Consumer Health FemHealth Focus
Astellas Singapore has announced that the Health Sciences Authority (HSA) of Singapore has approved VEOZA™ (fezolinetant) 45 mg for the treatment of ...
June 03, 2025 | News
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imagi...
May 20, 2025 | News
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...
May 19, 2025 | News
The Asia Pacific Initiative on Reproduction (ASPIRE) – the peak body harnessing expertise in assisted conception throughout the region – will e...
May 12, 2025 | News
TiumBio (KRX: 321550.KQ), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare a...
May 08, 2025 | News
Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastu...
May 08, 2025 | News
Breast cancer remains one of the leading health concerns in Indonesia and ranks as the third deadliest cancer after lung and liver cancer. According to the...
May 02, 2025 | News
Fertility specialists in the Asia Pacific region are bringing to fruition new standards of care for women and girls suffering from endometriosis and to hel...
May 01, 2025 | News
SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers in the United States, is proud to announce thei...
April 24, 2025 | News
Gene Solutions, a leading multinational biotech company specializing in advanced genetic testing, and Element Biosciences, a company democratizing acc...
April 23, 2025 | News
Contrast-enhanced ultrasound (CEUS) is a safe and accurate diagnostic imaging option for pregnant women who develop a medical problem or a suspicious tumor...
April 14, 2025 | News
Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody ...
April 11, 2025 | News
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free surviv...
April 04, 2025 | News
Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significan...
March 28, 2025 | News
Most Read
Bio Jobs
News
Editor Picks